Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline

C Lass-Flörl; M P Dierich; D Fuchs; E Semenitz; M Ledochowski

doi:10.1086/324589

Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline

Clin Infect Dis. 2001 Dec 15;33(12):E135-6. doi: 10.1086/324589. Epub 2001 Nov 7.

Authors

C Lass-Flörl¹, M P Dierich, D Fuchs, E Semenitz, M Ledochowski

Affiliation

¹ Institutes of Hygiene and Social Medicine, University of Innsbruck, Austria. Cornelia.Lass-Floerl@uibk.ac.at

PMID: 11700578
DOI: 10.1086/324589

Abstract

Three patients with premenstrual dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) underwent sertraline therapy (Tresleen, a selective serotonin-reuptake inhibitor; Pfizer) for PMDD. During sertraline intervention, patients had no recurrent episodes of acute VVC. Antifungal activity was observed for sertraline against various isolates of Candida species.

Publication types

Case Reports

MeSH terms

Adult
Antifungal Agents / pharmacology
Antifungal Agents / therapeutic use*
Candida / drug effects*
Candidiasis, Vulvovaginal / drug therapy*
Female
Humans
Premenstrual Syndrome / drug therapy*
Selective Serotonin Reuptake Inhibitors / pharmacology
Selective Serotonin Reuptake Inhibitors / therapeutic use*
Sertraline / pharmacology
Sertraline / therapeutic use*

Substances

Antifungal Agents
Serotonin Uptake Inhibitors
Sertraline